Sverige - svenska - Läkemedelsverket (Medical Products Agency)

bayer ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - levonorgestrel - intrauterint inlägg - 20 mikrogram/24 timmar - levonorgestrel 52 mg aktiv substans - plastiskt intrauterint preventivmedel med gestagen

Europeiska unionen - svenska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - noradrenalintartrat (monohydrat) - koncentrat till infusionsvätska, lösning - 1 mg/ml - noradrenalintartrat (monohydrat) 2 mg aktiv substans - noradrenalin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - adrenalin - injektionsvätska, lösning i förfylld spruta - 0,3 mg/dos - adrenalin 0,3 mg aktiv substans; natriummetabisulfit hjälpämne - adrenalin